Daniel W. Muehl, See Remarks at Clovis Oncology, Inc. (CLVS), sold 279 shares at $6.90 ($2K) on 2020-02-27, disclosed to the SEC on 2020-03-02.
Seasonal sale ($2k) by See Remarks — this insider has traded CLVS in February in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| CLVS | SELL | 2022-08-03 | $7K | — | Filing → |
| CLVS | SELL | 2022-06-03 | $1K | — | Filing → |
| CLVS | SELL | 2022-05-03 | $9K | — | Filing → |